Published in J Cardiovasc Transl Res on February 01, 2010
Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell (2012) 3.66
Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol (2010) 1.71
Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res (2011) 1.47
iPS cell-derived cardiogenicity is hindered by sustained integration of reprogramming transgenes. Circ Cardiovasc Genet (2014) 1.40
Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene Ther (2010) 1.21
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle (2013) 1.20
Cardiac tumorigenic potential of induced pluripotent stem cells in an immunocompetent host with myocardial infarction. Regen Med (2011) 1.08
Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol (2011) 1.04
Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells. PLoS One (2012) 0.98
New and TALENted genome engineering toolbox. Circ Res (2013) 0.96
Nuclear reprogramming with c-Myc potentiates glycolytic capacity of derived induced pluripotent stem cells. J Cardiovasc Transl Res (2012) 0.93
Low oxygen tension enhances proliferation and maintains stemness of adipose tissue-derived stromal cells. Biores Open Access (2013) 0.92
Nuclear reprogramming strategy modulates differentiation potential of induced pluripotent stem cells. J Cardiovasc Transl Res (2011) 0.90
ΔNp63 regulates select routes of reprogramming via multiple mechanisms. Cell Death Differ (2013) 0.89
Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines. Circ Cardiovasc Genet (2013) 0.83
Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy. Stem Cells Dev (2014) 0.81
Selection via pluripotency-related transcriptional screen minimizes the influence of somatic origin on iPSC differentiation propensity. Stem Cells (2014) 0.81
The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. Stem Cell Rev (2014) 0.80
c-Myc is required for proper coronary vascular formation via cell- and gene-specific signaling. Arterioscler Thromb Vasc Biol (2012) 0.80
Human cardiomyogenesis and the need for systems biology analysis. Wiley Interdiscip Rev Syst Biol Med (2010) 0.78
Cell Reprogramming, IPS Limitations, and Overcoming Strategies in Dental Bioengineering. Stem Cells Int (2012) 0.77
Generation of Induced Pluripotent Stem (iPS) Cells by Nuclear Reprogramming. Stem Cells Int (2011) 0.77
Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery. Regen Med (2015) 0.77
Systems-based technologies in profiling the stem cell molecular framework for cardioregenerative medicine. Stem Cell Rev (2015) 0.75
De novo myocardial regeneration: advances and pitfalls. Antioxid Redox Signal (2010) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol (2007) 21.93
Disease-specific induced pluripotent stem cells. Cell (2008) 16.95
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (2008) 14.26
Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science (2007) 12.41
Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell (2008) 12.29
c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell (2007) 8.46
Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell (2008) 7.57
Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A (2008) 7.52
Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res (2009) 7.09
Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature (2009) 7.04
Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell (2007) 6.62
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature (2009) 5.37
Elite and stochastic models for induced pluripotent stem cell generation. Nature (2009) 5.06
Epigenetic reprogramming and induced pluripotency. Development (2009) 4.90
Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A (1988) 4.23
The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol (2008) 3.56
Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A (2009) 3.43
c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev (2002) 3.16
Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation (2008) 3.11
Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation (2008) 3.11
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS One (2008) 2.51
Cardiogenesis and the complex biology of regenerative cardiovascular medicine. Science (2008) 2.30
Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A (2009) 2.02
Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med (2007) 1.97
Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells (2008) 1.83
Pluripotency and nuclear reprogramming. Philos Trans R Soc Lond B Biol Sci (2008) 1.82
iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res (2009) 1.77
The c-myc proto-oncogene regulates cardiac development in transgenic mice. Mol Cell Biol (1990) 1.76
Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol (2004) 1.73
Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts. PLoS One (2009) 1.47
Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res (2001) 1.44
Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway. EMBO J (2006) 1.41
c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Blood (2009) 1.23
Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport machinery. Nat Clin Pract Cardiovasc Med (2007) 1.21
Induced pluripotent reprogramming from promiscuous human stemness related factors. Clin Transl Sci (2009) 1.20
Stem cells: biologics for regeneration. Clin Pharmacol Ther (2008) 1.14
Structural adaptation of the nuclear pore complex in stem cell-derived cardiomyocytes. Circ Res (2003) 1.11
Stem cell platforms for regenerative medicine. Clin Transl Sci (2009) 1.01
KCNJ11 knockout morula re-engineered by stem cell diploid aggregation. Philos Trans R Soc Lond B Biol Sci (2009) 0.99
Lineage specification of Flk-1+ progenitors is associated with divergent Sox7 expression in cardiopoiesis. Differentiation (2008) 0.99
Strategies for therapeutic repair: The "R(3)" regenerative medicine paradigm. Clin Transl Sci (2008) 0.97
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol (2013) 5.11
Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab (2011) 4.15
Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature (2002) 3.60
Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med (2005) 3.59
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet (2006) 3.15
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet (2004) 2.85
Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol (2008) 2.81
Phosphotransfer networks and cellular energetics. J Exp Biol (2003) 2.79
Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A (2002) 2.60
Stem cell differentiation requires a paracrine pathway in the heart. FASEB J (2002) 2.55
Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation (2005) 2.42
Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol (2004) 2.39
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell (2012) 2.36
Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med (2007) 2.32
Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J Cell Biol (2006) 2.24
Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med (2007) 2.21
Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J Physiol (2006) 2.06
Cardiac KATP channels in health and disease. J Mol Cell Cardiol (2005) 2.04
Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol (2006) 2.01
Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med (2007) 1.97
Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat Cell Biol (2012) 1.94
Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science (2004) 1.93
Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol (2010) 1.82
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2011) 1.78
iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res (2009) 1.77
KATP channel knockout worsens myocardial calcium stress load in vivo and impairs recovery in stunned heart. Am J Physiol Heart Circ Physiol (2006) 1.74
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74
Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol (2004) 1.73
Coupling of cell energetics with membrane metabolic sensing. Integrative signaling through creatine kinase phosphotransfer disrupted by M-CK gene knock-out. J Biol Chem (2002) 1.72
Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol (2010) 1.71
Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol (2006) 1.70
Altered intracellular Ca2+ handling in heart failure. J Clin Invest (2005) 1.70
Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci (2009) 1.67
CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells. Stem Cells (2008) 1.63
Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc (2009) 1.62
Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res (2010) 1.61
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol (2012) 1.61
KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med (2007) 1.56
Knockout of Kir6.2 negates ischemic preconditioning-induced protection of myocardial energetics. Am J Physiol Heart Circ Physiol (2003) 1.56
Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation (2012) 1.56
KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet (2006) 1.53
ATP-sensitive K+ channel knockout compromises the metabolic benefit of exercise training, resulting in cardiac deficits. Diabetes (2004) 1.53
Tongue muscle-derived stem cells express connexin 43 and improve cardiac remodeling and survival after myocardial infarction in mice. Circ J (2010) 1.50
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol (2007) 1.49
Identification and physiological activity of survival factor released from cardiomyocytes during ischaemia and reperfusion. Cardiovasc Res (2008) 1.49
Lentiviral vectors: basic to translational. Biochem J (2012) 1.49
Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol (2013) 1.47
Mitochondrial tolerance to stress impaired in failing heart. J Mol Cell Cardiol (2003) 1.45
Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem (2004) 1.42
Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Pract Cardiovasc Med (2006) 1.41
Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. EMBO J (2003) 1.40
Energetic communication between mitochondria and nucleus directed by catalyzed phosphotransfer. Proc Natl Acad Sci U S A (2002) 1.40
Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. Stem Cells (2008) 1.39
ATP-sensitive K+ channel channel/enzyme multimer: metabolic gating in the heart. J Mol Cell Cardiol (2005) 1.38
Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. J Mol Cell Cardiol (2010) 1.37
Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration. Proc Natl Acad Sci U S A (2012) 1.37
The mechanism of Axl-mediated Ebola virus infection. J Infect Dis (2007) 1.36
Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant (2010) 1.34
Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest (2004) 1.33
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33
Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation. Am J Physiol Heart Circ Physiol (2002) 1.32
Sarcolemmal ATP-sensitive K(+) channels control energy expenditure determining body weight. Cell Metab (2010) 1.31
Clinical and translational science: from bench-bedside to global village. Clin Transl Sci (2010) 1.30
Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther (2005) 1.30
Tandem function of nucleotide binding domains confers competence to sulfonylurea receptor in gating ATP-sensitive K+ channels. J Biol Chem (2002) 1.29
Gene knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal susceptibility to endotoxemia. FASEB J (2006) 1.28
Defective domain-domain interactions within the ryanodine receptor as a critical cause of diastolic Ca2+ leak in failing hearts. Cardiovasc Res (2008) 1.27
K(ATP) channel therapeutics at the bedside. J Mol Cell Cardiol (2005) 1.27
Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol (2004) 1.26
Nucleotide-gated KATP channels integrated with creatine and adenylate kinases: amplification, tuning and sensing of energetic signals in the compartmentalized cellular environment. Mol Cell Biochem (2004) 1.26
Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol (2007) 1.24
Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology (2012) 1.24
Genetic disruption of Kir6.2, the pore-forming subunit of ATP-sensitive K+ channel, predisposes to catecholamine-induced ventricular dysrhythmia. Diabetes (2004) 1.23
Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation (2005) 1.23
Disease-causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from a patient with MELAS. Stem Cells (2013) 1.22
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology (2011) 1.22
Stem cells transform into a cardiac phenotype with remodeling of the nuclear transport machinery. Nat Clin Pract Cardiovasc Med (2007) 1.21
Translating MicroRNA discovery into clinical biomarkers in cancer. JAMA (2007) 1.20
Induced pluripotent reprogramming from promiscuous human stemness related factors. Clin Transl Sci (2009) 1.20
Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol (2009) 1.20
Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology (2012) 1.20
Aging and cardioprotection. J Appl Physiol (1985) (2007) 1.20
Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration. Am J Pathol (2008) 1.20
Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol Ther (2012) 1.19
Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology (2009) 1.19
Potassium channel openers are uncoupling protonophores: implication in cardioprotection. FEBS Lett (2004) 1.18
No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology (2011) 1.18